Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis

  title={Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis},
  author={Zhilan Yang and Ying Hu and Jing Zhang and Liangzhi Xu and Rujun Zeng and Deying Kang},
  journal={Gynecological Endocrinology},
  pages={87 - 92}
Abstract Objective: To investigate the association between estradiol therapy and incidence of breast cancer, taking into consideration of different types of combined progestogen, the duration of exposure and the type of regimen. Method: A systematic review and meta-analysis. Result: A total of 14 studies were included in our study. In estradiol-only therapy analysis, meta-analysis resulted a pooled OR =0.90, 95% CI (0.40, 2.02) from the RCTs and pooled OR = 1.11, 95% CI (0.98, 1.27) from… 

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial

Results of secondary outcomes suggest that E2/P4 may not be associated with increased risk of abnormal mammograms versus placebo, and the incidence of breast tenderness was low relative to most of the rates reported in other studies using hormone therapy.

Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.

The role of hormone therapy in menopausal patients with breast cancer and gynecologic malignancies is reviewed to determine whether it is considered safe in low-risk cancers but should be avoided in high-risk subtypes.

Menopausal Hormone Therapy Formulation and Breast Cancer Risk

Although menopausal HT use appears to be associated with an overall increased risk of breast cancer, this risk appears predominantly mediated through formulations containing synthetic progestins, which may be the safer progestogen to be used.

Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins.

Evidence suggests a differential effect of MHT containing E2 or P4 and those containing CEE or progestins, with some evidence trending to a potentially better safety profile with E2 and/or P4.

The impact of micronized progesterone on breast cancer risk: a systematic review

Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection and should also be counseled on other modifiable and non-modifiable breast cancer risk factors in order to balance the impact of combined MHT on the breast.

WITHDRAWN – Administrative Duplicate Publication: Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis

This consensus statement provides an overview of the association between HRT and breast cancer outcomes in women at low and higher risk of breast cancer.

Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk

  • D. TanA. R. B. Dayu
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2022
There are five interrelated reasons why physicians and women should no longer be afraid of the breast cancer risk with EPRT, and avoiding MHT use when indicated puts a woman in harm’s way.

Update on Menopausal Hormone Therapy for Fracture Prevention

Menopausal hormone therapy should be considered in women with premature estrogen deficiency and increased risk of bone loss and osteoporotic fractures, but use is hindered by increase in breast cancer risk even in women younger than 60 years old or who are within 10 years of menopause onset.

A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause

The combination bioidentical E2/P4 capsule (1 mg/100 mg dose was FDA-approved as Bijuva in October 2018) may provide a safe, effective, rigorously studied alternative for women with a uterus who prefer CHT for relief of VMS.

Evidence on the use of progesterone in menopausal hormone therapy

  • S. Mirkin
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2018
A regulatory agency-approved HT with naturally occurring E2/P4 could be an option for the millions of women who desire a bioidentical product and/or are exposed to potential risks of inadequately studied and under-regulated compounded HT.



Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis

Data from observational studies support the association of increased but considerably different risks for breast cancer incidence among current users of ET and CHT.

An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk

Results from the Women's Health Initiative (WHI) trial support findings from observational studies that oestrogen–progestin therapy (EPT) use is associated with an increase in breast cancer risk. We

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

The findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive, and breast cancer mortality also appears to be increased with combined use of estrogen plus proggestin.

Estrogen–progestin replacement therapy and breast cancer risk: the Women's Health Study (United States)

Use of estrogen–progestin replacement therapy imparts an increased risk of breast cancer in comparison with never use of PMH, and higher doses of estrogen, but not progestin, were associated with increased breast cancer risk, compared with lower doses.

Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition

Estrogen‐only and combined MHT uses and continuous combined preparations were associated with increased breast cancer risk, and Continuous combined preparations was associated with the highest risk.

Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations

Evidence is provided that the risk of developing gynecological cancers with E/D use of several months to a few years is similar to the risks of developing Gynecological cancer without HRT or use of other HRT.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Consistent with WHI randomized trial findings, estrogen plus progestin use is associated with increased breast cancer incidence and prognosis after diagnosis on combined hormone therapy is similar to that of nonusers, and increased breastcancer mortality can be expected.

Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis.

The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer, whereas estrogen use was not associated with mortality of other types of cancer.

Breast cancer risk with postmenopausal hormonal treatment.

Reasonably adequate data do not show that breast cancer risk varies significantly with different types of estrogen or progestin preparations, lower dosages or different routes of administration, although there is a small difference between sequential and continuous proggestin regimens.